Pharmaceutical Executive Daily
New research suggests Ozempic may reduce biological age.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
Recent Approvals and Research
- The FDA has approved Bayer’s Lynkuet for menopausal hot flashes.
- New research suggests Ozempic may reduce biological age.
- Novartis’ $12 billion merger agreement to acquire Avidity Biosciences.
The FDA approval of Lynkuet is based on Phase III OASIS trial data showing significant reductions in hot flash frequency and severity.
Lynkuet provides an important new therapeutic alternative for patients seeking relief from menopausal symptoms without estrogen exposure.
Author's summary: New research on Ozempic and FDA approval of Lynkuet.
More News
- Venture capital is not an asset class, says Sequoia's Roelof Botha | TechCrunch
- Alleged Charlie Kirk assassin allowed to wear street clothes at trial
- Feeling like a dog chasing his own tail in a country and a society out of control
- The Casandra Cascade: Industrialisation Of Fear - FNArena.com
- Venture Capital, Moonshots, and AI: The 2025 Tech Soap Opera
- Michael Clark murder defense seeks to link case to JonBenét investigation 'mistakes'
- Tim Marshall on how geography still matters in modern wars
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups